Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.1500 +0.0700 (+6.48%) 04/02/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.0900 -0.0600 (-5.22%) 19:34 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0500
Day High
1.1600
Open 1.0800
Previous Close 1.0800 1.0800
Volume 259,100 259,100
Avg Vol 796,730 796,730
Stochastic %K 24.82% 24.82%
Weighted Alpha -62.68 -62.68
5-Day Change -0.0900 (-7.26%) -0.0900 (-7.26%)
52-Week Range 1.0500 - 4.4200 1.0500 - 4.4200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,028
  • Shares Outstanding, K 45,396
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,610 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta 1.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.34

Options Overview Details

View History
  • Implied Volatility 225.10% ( +3.22%)
  • Historical Volatility 99.83%
  • IV Percentile 66%
  • IV Rank 31.51%
  • IV High 683.19% on 02/10/25
  • IV Low 14.38% on 06/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 65
  • Volume Avg (30-Day) 131
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 7,031
  • Open Int (30-Day) 7,375

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.34
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +9.52%
on 04/02/25
Period Open: 1.3300
1.4900 -22.82%
on 03/07/25
-0.1800 (-13.53%)
since 02/28/25
3-Month
1.0500 +9.52%
on 04/02/25
Period Open: 1.7300
2.2000 -47.73%
on 02/27/25
-0.5800 (-33.53%)
since 01/02/25
52-Week
1.0500 +9.52%
on 04/02/25
Period Open: 3.7200
4.4200 -73.98%
on 07/16/24
-2.5700 (-69.09%)
since 04/02/24

Most Recent Stories

More News
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

The company said the reduced losses were primarily due to decreased operating expenses.

VXF : 176.31 (+1.81%)
PDSB : 1.1500 (+6.48%)
VTI : 277.95 (+0.79%)
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

PDSB : 1.1500 (+6.48%)
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

PDSB : 1.1500 (+6.48%)
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

PDSB : 1.1500 (+6.48%)
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

PDSB : 1.1500 (+6.48%)
PDS Biotech Leadership to Participate in March Conferences

PDSB : 1.1500 (+6.48%)
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

PDSB : 1.1500 (+6.48%)
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PDSB : 1.1500 (+6.48%)
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

PDSB : 1.1500 (+6.48%)
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

PDSB : 1.1500 (+6.48%)

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 1.3000
2nd Resistance Point 1.2300
1st Resistance Point 1.1900
Last Price 1.1500
1st Support Level 1.0800
2nd Support Level 1.0100
3rd Support Level 0.9700

See More

52-Week High 4.4200
Fibonacci 61.8% 3.1327
Fibonacci 50% 2.7350
Fibonacci 38.2% 2.3373
Last Price 1.1500
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades